Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
|Videos|March 10, 2020
Including Women in HIV Research
Author(s)Contagion® Editorial Staff
Ian Frank, MD, discusses the need to include women in HIV research.
Advertisement
Segment Description: Ian Frank, MD, Professor of Medicine at the Hospital of the University of Pennsylvania, discusses the need to include women in HIV research.
Interview Transcript (modified slightly for readability):
Frank: Women are not included at the same proportion as the rate of infection in women in antiretroviral therapy clinical trials.
People should remember that worldwide there are as many women living with HIV infection as men. In the developed world we tend to focus on the epidemic among men who have sex with men, we think about intravenous drug users, but women are still getting infected. And they're not studied.
Or I would say, rather than not studied, they don't participate at the same frequency as men, in proportion to the numbers of individuals that are infected. We need to remember when we're talking about new drugs, when we're talking about new preventative strategies, that we need to include women in these studies, as we include men.
Advertisement
Related to this article
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
3
Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37
4
FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
5